Response to anti-PD1 therapy with nivolumab in metastatic sarcomas

BACKGROUND: Manipulation of immune checkpoints such as CTLA4 or PD-1 with targeted antibodies has recently emerged as an effective anticancer strategy in multiple malignancies. Sarcomas are a heterogeneous group of diseases in need of more effective treatments. Different subtypes of soft tissue and...

Descripción completa

Detalles Bibliográficos
Autores principales: Paoluzzi, L., Cacavio, A., Ghesani, M., Karambelkar, A., Rapkiewicz, A., Weber, J., Rosen, G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5200964/
https://www.ncbi.nlm.nih.gov/pubmed/28042471
http://dx.doi.org/10.1186/s13569-016-0064-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5200964/
https://www.ncbi.nlm.nih.gov/pubmed/28042471
http://dx.doi.org/10.1186/s13569-016-0064-0

Ejemplares similares